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Objective: Opioid prescription rates in North America have increased dramatically over 
the past two decades, but little is known about prenatal opioid use. The purpose of this study is to 
determine the prevalence of prescription opioid use among pregnant women in the U.S. and 
Canada, as well as the duration, timing, and indication of use and lastly, to provide a description 
of maternal characteristics of those who used opioids.  
 xii 
Methods: Data were collected between 2004-2018 from a prospective cohort of 1,035 
women in the MotherToBaby Pregnancy Studies. Prescription opioid use was self-reported. 
Results: Seven percent of women used any prescription opioids during pregnancy. Most 
used opioids to treat acute illnesses and injuries, during a single trimester of pregnancy. Similar 
proportions of use were found across Trimesters 1, 2, and 3. There were a higher proportion of 
women with low SES, low educational attainment, overweight or obese BMI scores, a history of 
miscarriages, a history of terminated pregnancies, tobacco use, and co-occurring health 
conditions among women who used prescription opioids than in women who did not. 
Conclusion: Prescription opioids were used in pregnancy, and more often by women with 
other factors that increase the risk of adverse pregnancy outcomes. These findings support the 
call for additional research to examine the risk of adverse pregnancy or birth outcomes 
associated with prenatal opioid use. 
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CHAPTER 1: INTRODUCTION  
Beginning in the mid-2000s, opioid-prescribing behaviors among U.S. health care 
providers steadily increased and ultimately peaked in 2012 with 81.3 prescriptions per 100 
Americans—an equivalent of approximately 255 million prescriptions.1,2 While there has been 
an overall decrease in prescribing practices (58.7 prescriptions per 100 Americans in 2017), 
select counties suffer disproportionate opioid burden.1 As of 2017, approximately 17% of adults 
in the U.S. filled at least one prescription for an opioid.2  
Like the general population, pregnant women experience chronic conditions and acute 
ailments that may warrant the use of opioid pain relievers. However, since opioid prescriptions 
increased in just the past two decades, evidence of opioid use in pregnant women has just started 
to emerge in the past few years with the majority focused on illicit opioids (heroin) or medication 
assisted treatments for opioid addiction (e.g. methadone). Like with any medication taken during 
pregnancy, it is crucial to evaluate the safety of opioid use for both the mother and fetus and the 
potential long-term outcomes that may be associated with prenatal opioid use. Clarifying the 
scope of prenatal prescription opioid use is an essential first step in understanding the public 
health impact of this trend. 
 The purpose of this research is to identify in a large cohort of pregnant women 
throughout the United States and Canada, the prevalence of prescribed opioid use during 
pregnancy, as well as the duration of use, timing of use (pregnancy trimester), indication(s) of 
use, and any maternal characteristics that may be associated with increased likelihood for use. By 
describing these factors, this study will inform the design of future research intended to 
understand how timing, dose, and duration of use, as well as underlying medical conditions, 
contribute to reported adverse perinatal outcomes.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Background 
Opioid is an all-encompassing term to describe substances either derived from opium 
naturally found in poppy plants or a combination of both natural opium and a mixture of 
chemicals or other synthetic ingredients.3 Examples of natural opioid analgesics—also referred 
to as ‘opiates’—include morphine and codeine.4,5 Common semi-synthetic opioids include 
oxycodone, hydrocodone, hydromorphone, and oxymorphone, while methadone, tramadol, 
propoxyphene, and fentanyl are classified as fully synthetic opioid analgesics. 4,5  Many common 
prescription opioid brands, including Vicodin® (hydrocodone bitartrate and acetaminophen), 
Percocet® (oxycodone and acetaminophen), Tylenol #3® and #4® (codeine containing 
acetaminophen), and Ultracet® (tramadol hydrochloride and acetaminophen), contain both 
opioids as well as other non-opioid pain relievers such as acetaminophen, aspirin, and 
ibuprofen.5 Prescription opioids can be taken in several different forms, including tablets, 
capsules, skin patches, liquid (to be consumed orally or intravenously), nasal sprays, and 
“lollipops” (dissolvable substance on a stick, to be taken orally).6 
Opioids relieve pain and relax the body by activating opioid receptors that release 
dopamine and inhibit the brain from receiving pain signals.3,5 While they are mainly used to treat 
moderate to severe pain, opioids have also been effective as cough suppressants, diarrhea 
relievers, and sleep disorder treatments.6 The Centers for Disease Control and Prevention (CDC) 
recognize several side effects from opioids including constipation, nausea, vomiting, dry mouth, 
fatigue, dizziness, depression, confusion, lowered testosterone, itching, and sweating.7 Opioid 
use can lead to tolerance (needing more frequent and/or higher doses to relieve pain) and 
dependence that results in physical withdrawal symptoms when medication is stopped.7  
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In the United States, the Controlled Substances Act (CSA) requires all drugs to be 
categorized within one of five schedules based on their ability to serve a medical purpose, 
whether they can be misused or abused, their potential for creating dependence or addiction, and 
overall safety.6 According to the 2017 Drug Enforcement Agency (DEA) Resource Guide, the 
common opioids, morphine, oxycodone, hydrocodone, hydromorphone, propoxyphene, codeine, 
and fentanyl, are considered “Schedule II Narcotics,” due to their high potential for abuse and for 
severe physical and psychological dependence.6 The term ‘narcotic’ describes opioids from a 
legal perspective and does not denote scientific meaning.5 However, unlike the largely illicit 
group of drugs in the Schedule I class, opioids provide a necessary medical purpose.6  
 
2.2 Prescription Opioid Trends in the U.S. & Canada 
The CDC estimates 43% of American adults experience some kind of pain (i.e. chronic, 
acute, episodic, etc.) involving the musculoskeletal system alone (e.g. back pain, headaches, 
arthritis, etc.).8 Results from the 2012 National Health Interview Study showed 11.2% of adults 
report experiencing pain daily.8 In an attempt to tackle the unaddressed pain plaguing 
Americans, the American Pain Society (APS) campaigned in the mid-1990s for “pain” to be 
officially considered a “5th vital sign” in addition to the four other standard vital signs: body 
temperature, blood pressure, heart rate, and respiratory rate.9,10 By the early 2000s, this standard 
was widely accepted and ultimately put into practice, largely due to the Joint Commission’s 
(TJC) “published standards for pain management in 2000.”11 Along with a political shift in 
health care standards, there was a simultaneous boom in opioid availability due to increased 
pharmaceutical development of the late 1990s and early 2000s.11 These two concurrent factors 
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are considered the impetus for the large spike in opioid prescribing that ultimately peaked in the 
mid 2010s and arguably has led to the current opioid epidemic in the United States.11  
In 2017, there were 191 million opioid prescriptions filled in the United States, which 
were prescribed to about 17% of the population for an average of 18 days per prescription.2,7 In 
Canada, an estimated 13% of the population (approx. 4.6 million Canadians) received 
prescriptions for opioids in 2018.12 Of those who received an opioid prescription, 17.6% received 
an opioid prescription for long-term use.12 More than half (62.8%) of these patients prescribed 
opioids for long-term use were prescribed “strong” opioids (defined as “all fentanyl, 
hydromorphone, morphine, and oxycodone products”) typically reserved for severe pain 
associated with surgery or cancer.12 Despite a slight decrease in prescribing in both the U.S. and 
Canada, the CDC recognizes that as of 2017, “the amount of opioids in morphine milligram 
equivalents (MME) prescribed per person is still around three times higher than it was in 1999.”2 
In the U.S., prescribing rates are also disproportionately higher for people who are unemployed, 
uninsured, have arthritis, have a disability or are white.2 Unsurprisingly, with the increased use 
of opioids in general, there has been an increase in the misuse of opioids as well.11,13  
 
2.3 Opioid Misuse, Opioid Epidemic, and Response 
Prescription opioid use is considered ‘misuse’ if it is taken in a way that it was not 
intended per the prescribing physician (i.e. different method of consumption, different dose, 
taking for longer than prescribed, etc.), if it is taken by someone other than the patient who 
received the prescription, or if it is taken for recreational purposes.3 In 2016, 11.5 million 
Americans admitted to misusing prescription opioids, though the actual amount is likely greater.7 
Opioids inherently produce “euphorigenic or pleasurable effects” as a result of opioid receptors 
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binding endorphins, which involves the brain’s reward system.5 The probability that someone 
will use opioids a year after being prescribed increases abruptly after the five days of use, 
suggesting that physical dependence can occur less than a week after initiation of use.14 The 
CDC also recommends that opioids given for acute pain typically requires a prescription of three 
days or less and very rarely requires prescriptions longer than seven days.6 The National Institute 
on Drug Abuse’s (NIDA) Prescription Opioids and Heroin Research Report Series from 2018 
concluded, “prescription opioid use is a risk factor for heroin use.”15 The pooled data from 2002-
2012 showed an incidence of heroin use 19 times higher for those who had “prior nonmedical 
pain reliever use” than the general population.15 While only a small amount of people who use 
prescription opioids will later use heroin, 80% of heroin users claimed to have used prescription 
opioids before ever using heroin.15 It is important to note that the report does not clarify whether 
the prior prescription opioid use was lawfully prescribed nor whether it was being misused.  
Of the 42,000 opioid overdose deaths in 2016 throughout the U.S., 40% were estimated 
to be from prescription opioids.16 In 2017, the number of overdose deaths increased to nearly 
48,000 people.17 The opioid epidemic of the past decade has led to a substantial reduction in 
prescribing rates and an overall change in both the public and health care providers’ attitudes 
regarding the use of opioids as pain relievers. In 2019, the Canadian Pharmacists Association 
recommended that Canadian law be changed to require a prescription for any medication 
containing codeine.18 Currently, medications containing acetaminophen with codeine are over 
the counter (OTC) in all but one Canadian province.19  
The CDC also responded to the opioid crisis by publishing a set of evidence-based 
recommendations for prescribing opioids for chronic pain in 2016.8 In this guideline, chronic 
pain is defined as “pain conditions that typically last >3 months or past the time of normal tissue 
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healing” and long-term opioid use is defined as “use of opioids on most days for >3 months.”8 
Because of the risks associated with long-term opioid use, they recommend “nonpharmacologic 
therapy and nonopioid pharmacologic therapy” as the primary treatment options for people 
experiencing chronic pain.6 Opioids should only be prescribed in these cases if the benefits will 
outweigh the risks.6 If opioids are prescribed, they should be given at the lowest effective 
dosage, should be immediate-release rather than extended-release, and should be combined with 
nonpharmacologic and/or nonopioid pharmacologic therapies.6 To avoid accidental overdose, 
providers should avoid prescribing concurrently with benzodiazepines.6 The guideline also 
emphasizes the importance of screening patients for current addiction and to avoid prescribing 
any opioids to those with a heightened chance of developing addiction.6  
Despite a modest decline in opioid prescriptions and increased caution among prescribers 
in the U.S. and Canada, providers continue to prescribe opioids to pregnant women. Misuse of 
opioids during pregnancy also mirrors the rise in misuse among the general population during the 
same time. Among women who have delivered in hospitals, the number who were misusing 
opioids increased by 127% between 1998 and 2011.20 Currently, there is far less evidence 
describing prescription opioid use among pregnant women than there is describing opioid abuse 
and addiction among pregnant women.   
 
2.4 Emerging Evidence: Birth Complications and Fetal Outcomes 
While more evidence on current prescription opioid use among pregnant women in the 
U.S. and Canada is needed, the existing evidence on pregnant women with opioid abuse 
disorders has allowed for the emergence of several studies on pregnancy and fetal outcomes that 
were correlated with prenatal opioid use.  For example, in a nationally representative pediatric 
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inpatient database of hospital discharge summaries, antepartum maternal misuse/dependency at 
the time of delivery increased 1.19 to 5.63 per 1,000 hospital births per year between 2000 and 
2009.21 With the increase in maternal opioid abuse in the past decade has also been an increase in 
neonatal abstinence syndrome (NAS).21 NAS occurs when the fetus develops opioid dependency 
in the womb and experiences withdrawal once born.21 From the same pediatric inpatient 
database, incidence of NAS also increased from 2000-2009, rising from 1.20 to 3.39 per 1,000 
hospital births.21 The study’s investigators also report that mothers with diagnosis of opioid 
dependence or misuse were more likely to be Medicaid recipients than mothers that did not use 
opioids during pregnancy.21  
Several of these authors also conducted a second analysis to assess incidence and 
geographic distribution of NAS in the U.S. for the years following those in the first investigation. 
Between 2009 and 2012 there was an additional increase in incidence of NAS: 3.4 to 5.8 per 
1,000 hospital births respectively.22 Both studies found similar associations between NAS and 
birth complications. Babies born with NAS were more likely than their non-NAS counterparts to 
have low birth weight, respiratory problems, feeding difficulties, seizures, jaundice, and 
sepsis.21,22 Although NAS is a transient condition, the long-term consequences of prenatal opioid 
exposure have not been well studied. 
While heavier and more consistent use of opioids during pregnancy is most often 
associated with NAS, opioids can cross the placental and blood brain barriers, meaning that the 
fetus may receive exposure to the drug regardless of how heavily the mother uses. The biological 
effects of opioid exposure in the womb, if any, are not well understood. However, early 
explorations of outcomes have shown that opioid use during pregnancy is a risk factor for 
pregnancy complications and adverse birth outcomes.3,8,23-29 Results from these studies have 
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demonstrated that maternal opioid use was associated with increased risk of severe pregnancy 
complications, including spontaneous abortion,3,8,23 membrane ruptures,23,24 preeclampsia,23 
placental abruption,23 and Cesarean delivery.24,25 Maternal opioid use was also associated with 
risk of detrimental birth outcomes such as premature labor or birth,8,23,24,26-28 low birth 
weight,3,26,27 congenital abnormalities,23,26,27 admission to neonatal care unit,24 worse Apgar 
scores,24 neonatal sepsis,24 fetal intracranial hemorrhage,24 and fetal or infant death (including 
stillbirth,27,28 sudden infant death syndrome (SIDS),29 and death from all causes23,24,29). Many of 
these studies only included women with substance use disorders rather than all women who were 
prescribed opioids. This distinction is crucial since women with substance use disorders may be 
using opioids more frequently and at higher doses than those prescribed and may also be abusing 
other substances that contribute to these same outcomes. Some of these studies also had 
relatively small samples and were only focused on the biological effects of one type of opioid. 
Despite the lack of large-scale, generalizable results, organizations that oversee maternal and 
child health explicitly listed opioid use as a risk for these complications.8,28,30,31 This decision 
was likely made to deter the prescription of opioids to pregnant women due to the seriousness of 
the outcomes exhibited in these early studies. 
Emerging evidence suggest that opioids taken just before conception or during the early 
weeks of pregnancy impact a fetus’s risk of some birth defects. In a case-control study of 
mothers of babies with and without particular birth defects, there was a statistically significant 
association between opioid use during pregnancy and risk of several heart defects, spina bifida, 
and gastroschisis.32 Another case-control study compared mothers of babies with neural tube 
defects (cases), mothers of babies with another kind of malformation (first control group), and 
mothers of babies with no defects (second control group) between 1998 and 2010.33 The 
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researchers found that mothers of children with neural tube defects were more likely to report 
using opioids during pregnancy than both the malformed control group (OR 1.9) and the non-
malformed control group (OR 2.2).33 The associations were stronger when comparing those who 
had children with spina bifida specifically (OR 2.2 and 2.5, respectively).33 The most commonly 
reported opioids among users in this study were codeine, oxycodone, and hydrocodone.33  
Despite these early findings from case-control studies, there is mixed evidence about 
whether opioids are teratogenic drugs. A large population-based cohort study found no 
differences in the malformation rate between fetuses who were exposed to codeine in the womb 
and those who were not exposed.25 A 2017 systematic review determined the quantity and 
quality of the existing studies to be insufficient for verifying a clear association between opioid 
use during pregnancy and congenital malformations.20  
A Morbidity and Mortality Weekly Report (MMWR) published in 2019 highlights an 
ecologic link between rates of opioid prescriptions and gastroschisis prevalence.34 Overall, 
gastroschisis prevalence has increased by 10% from 2006-2010 to 2011-2015 in the United 
States.34 In this timeframe, the prevalence of gastroschisis was 1.6 times higher in high-
prescribing counties (5.1 per 10,000 live births) and 1.4 times higher in moderate-prescribing 
counties (4.6 per 10,000 live births) than in low-prescribing counties (3.2 per 10,000 live 
births).34 However, there are several limitations in this study including the fact only 20 states are 
included, possible confounders are not addressed in the analysis, and possible biological 
mechanisms linking the exposure and outcome are not known.  
More recently, case-control studies examining an association between prescription opioid 
use during pregnancy and learning disabilities, developmental disorders, and autism have been 
conducted. A study using Tennessee Medicaid and birth certificate data linked to data from the 
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Tennessee Department of Education examined children between the ages of 3-8 years old.35 
Investigators matched 1,815 children born with NAS with 5,441 children without.35 After 
controlling for potential confounders, such as maternal education, perinatal smoking, low birth 
weight, preterm birth, and NICU admission, children born with NAS were significantly more 
likely to “be referred for a disability evaluation” (19.3% vs. 13.7%, respectively), “meet criteria 
for a disability,” (15.6% vs. 11.4%, respectively), and “require classroom therapies or services” 
(15.3% vs. 11.4%, respectively).35 A 2019 case-control study comparing children with autism 
spectrum disorder only, children with a developmental delay/disorder (no autism features) only, 
children with either autism spectrum disorder or developmental delay/disorder with autism 
features, and population controls (total of ~2,800 cases and ~1,500 controls) also found an 
association with opioid use immediately before pregnancy and risk of having a child with 
hindered developmental outcomes.36 The authors found, after adjusting for confounders, having a 
“preconception opioid prescription” was associated with risk of having a child with autism 
spectrum disorder (OR 2.43) and having either autism spectrum disorder and/or a developmental 
disorder with autism features (OR 2.64).36 Like the majority of other studies, participants 
received prescriptions for hydrocodone, oxycodone, and codeine prescriptions more frequently 
than other types of opioids.36  
While more studies are needed, those that exist support the CDC’s “Pregnancy and 
Opioid Pain Medications” factsheet suggesting that these studies have yielded enough evidence 
to justify caution when prescribing opioids to women who are or may become pregnant.28 The 
factsheet lists “neonatal opioid withdrawal syndrome, neural tube defects, gastroschisis, 
congenital heart defects, stillbirth, and preterm delivery” as possible risks when taking opioids 
during pregnancy.28  
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2.5 Current Recommendations 
The American College of Obstetricians and Gynecologists (ACOG) produced a set of 
official recommendations for obstetrics/gynecology (OB/GYN) care in 2017. The committee, 
which included input from the American Society of Addiction Medicine, reaffirmed their 
recommendations in 2019. As with health care providers of any specialty, it is recommended that 
patients are screened for opioid use and opioid use disorders.30 The guidelines also suggest 
hesitancy when prescribing opioids for pregnant patients who experience chronic pain.30 The 
preferred pain treatments include physical therapy, exercise, behavioral methods, or non-opioid 
medications.30  Even patients who are not pregnant but are of reproductive age should be 
informed about how if she were to become pregnant, the treatment plan may change depending 
on the risks and benefits for that individual.30 Before prescribing opioids, the ACOG 
recommends the OB/GYN: 1) discuss with the mother the costs/benefits of using opioids during 
pregnancy, 2) determine the patient’s substance abuse history, and 3) “ensure that opioids are 
appropriately indicated.”30 Despite their strict parameters for prescribing opioids to pregnant 
women, the ACOG notes that “acute pain” should not be left untreated in pregnant patients 
simply due to a physician’s “concern for opioid misuse or NAS.”30  
In 2018, the Royal College of Obstetricians and Gynaecologists (RCOG) published 
recommendations that corroborate the claims that ACOG produced a year earlier. While both 
organizations discourage providers from withholding treatment for their pregnant patients, the 
RCOG actually claims that by doing so, the patient could develop anxiety and depression, which 
can have negative impacts on the pregnancy.31 The RCOG reports acetaminophen is the first 
pharmacological choice for treating mild to moderate pain because it can be used during any 
trimester without fear of birth defects.31 Often, if women are experiencing pain that cannot be 
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relieved by acetaminophen, such as severe migraines, autoimmune disease pains, etc., 
nonsteroidal anti-inflammatory drugs (NSAIDs) can be prescribed.31 However, if providers are 
to prescribe an NSAID, it should be at the lowest dose, for the shortest duration, and only during 
the first 30 weeks of pregnancy.31 Similarly, opioids should only be prescribed to pregnant 
patients if acetaminophen and other remedies fail to alleviate the pain.31 The RCOG does not 
condemn the prescription of opioids after 30 weeks, but suggests the smallest dose and shortest 
duration possible to avoid fetal respiratory depression.31 Still, the RCOG urges providers to 
address pain in pregnant patients using non-pharmacological treatments first.31 The ideal pain 
alleviation methods include relaxation and rest, using heat and ice, acupuncture, massage, 
physical therapy, and exercise.31  
 
2.6 Study Objectives 
To date, our understanding of prescription opioid use in pregnancy primarily derives 
from Medicaid studies,37,38 which rely on administrative claims and over-represent minority and 
low-income women. Administrative claims, which describe the filling of prescriptions, may 
diverge from actual use, particularly for medications taken ‘as needed.’ The profile of women in 
the U.S. or Canada who use prescription opioids in pregnancy, particularly outside of the public 
insurance system, has not been identified. Without adequate existing evidence, we also lack the 
ability to make informed analytical adjustments and contextualization of any findings. This is 
particularly pronounced in studies of offspring outcomes, where the underlying maternal 
characteristics and medical comorbidities of women using prescription opioids in pregnancy are 
often unknown, and therefore residual confounding by these factors is of concern.  Therefore, 
this analysis aims to describe, from a relatively healthy sample, the type of woman that uses 
 13 
prescription opioids during pregnancy, as well as why the opioid was prescribed, when and for 
how long the opioid they were taken, and which types of opioids were prescribed. This initial 
descriptive study aims to lay the necessary groundwork for forthcoming research examining the 
safety of perinatal opioid exposure and long-term effects for both the mother and the fetus. 
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CHAPTER 3: METHODS 
 
3.1 Data Source 
3.1.1 Background 
The nonprofit organization, Organization of Teratology Information Specialists (OTIS), 
conducts a variety of maternal and child health studies in conjunction with their 
“MotherToBaby” pregnancy counseling service. The counseling service is provided at several 
sites across the U.S. and Canada where women can ask experts about the risks associated with 
certain exposures during pregnancy, such as medications, environmental exposures, infections, 
maternal health conditions, herbal products, cosmetics, and so on.39-41 The MotherToBaby 
service also comprises research teams that conduct observational studies on these types of 
exposures during pregnancy and breastfeeding to examine associations with maternal, child, and 
pregnancy outcomes.39 MotherToBaby research studies are funded through grants from the CDC, 
the Health Resources and Services Administration at the U.S. Department of Health and Human 
Services,42 pharmaceutical companies for post-marketing surveillance studies, and grants 
through the National Institutes of Health.  
3.1.2 Study Design & Data Collection 
Pregnant women across the U.S. and Canada are recruited to participate in a 
MotherToBaby Pregnancy Study in several ways, such as through referral from their physician 
or through direct advertisements.40,41,43 The most common recruitment approach is referring the 
women who call the MotherToBaby counseling service to the Pregnancy Studies. 40,41,43 There 
were 4,233 women who were enrolled prior to 20 weeks gestation in a MotherToBaby research 
study between 2004-2018. Informed consent was obtained from all enrolled participants. 
Immediately after enrolling, researchers conducted a semi-structured one-on-one telephone 
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interview. In addition to this baseline interview, participants were interviewed up to three more 
times (depending on their gestational age at enrollment) at ~24 weeks gestation, ~32 weeks 
gestation, and after birth.43 Data collected via interviews include demographic information, 
medical histories, and information on exposures and outcomes. The researchers conducting these 
interviews were trained both directly by the supervisors as well as through observation of live 
interviews and could not conduct an interview alone until the study supervisor deemed it 
appropriate.40  
 
3.2 Measures 
3.2.1 Exposure 
Prescription opioid exposure was defined as any use of a prescription opioid that has been 
prescribed specifically to that participant by a licensed health care provider. Participants reported 
opioid use through daily diaries. Based on the participant’s last menstrual period (LMP), which 
was used to define the beginning of the pregnancy, data were then recoded to display “any use 
(yes/no)” by week of pregnancy (ranging from 1 week before LMP up to 42 weeks gestation or 
delivery depending on which came first). Exposure to more than one opioid on a given day or 
week were not double-counted as the variable was coded as binary (yes, used or no, have not 
used).  
Women also reported the type or brand of opioid used as well as the indication for use 
(multiple indications could be reported for each exposure or across exposure periods). These 
indications were separated into chronic and acute categories. Chronic categories include chronic 
pain, chronic migraines, and autoimmune disease(s). Acute categories include acute illness or 
injury, surgery or procedure, cold or flu, and ER visit (specific indication unknown). Opioid 
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classification was separated by type of opioid based on either explicit report or by recoding the 
specific brand that was reported.  
3.2.2 Covariates 
During the baseline interview, participants reported their age, race, ethnicity 
(Hispanic/Latina or not), whether their pregnancy was planned, prenatal vitamin use, parity, 
miscarriage history, terminated pregnancy history, and for multigravida women, whether there 
has been a paternity change prior to this pregnancy. Geographic data for participants included 
their state or province and country of origin, which were grouped into region based on the United 
States Census Bureau Regions and Divisions.44 The “Northeast” region includes Maine, New 
Hampshire, Vermont, Massachusetts, Connecticut, Rhode Island, Pennsylvania, New York, and 
New Jersey. The “South” region includes the District of Columbia, Maryland, Delaware, 
Virginia, West Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Georgia, Florida, 
Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and Texas. The “Midwest” region 
includes Ohio, Indiana, Illinois, Missouri, Kansas, Nebraska, Iowa, Michigan, Wisconsin, 
Minnesota, North Dakota, and South Dakota. The “Mountain” region included New Mexico, 
Arizona, Colorado, Utah, Nevada, Idaho, Wyoming, and Montana. Lastly, the “Pacific” region 
included Washington, Oregon, California, Hawaii, and Alaska. Because of the comparatively 
small number of Canadian participants in this sample, all Canadian provinces were grouped 
together under the category, “Canada.” 
Pre-pregnancy height and weight were used to determine pre-pregnancy body mass index 
(BMI). BMI was then categorized using the standardized BMI score chart into “underweight” 
(BMI <18.5), “normal weight” (18.5 ≤ BMI < 25), and “overweight or obese” (BMI > 25).45 
Highest education level and occupation were used to estimate Hollingshead socioeconomic 
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status (SES), with scores of 5-6 categorized as low SES.46 Women also indicated whether they 
had previously been diagnosed with an autoimmune disease, asthma, depression, anxiety 
disorder, or other mental health disorder. Throughout the pregnancy, women reported 
antidepressant use, any tobacco consumption, last week of alcohol consumption, and first week 
of prenatal vitamin use. After birth, delivery method and gestational age at delivery (in weeks) 
were recorded.  
 
3.3 Sample 
For this study, all women in the MotherToBaby database were eligible if they had 
originally enrolled before their 20th week of gestation (n=4,161). To have complete capture of 
opioid use across gestation, this sample was restricted to only include women who had live 
births, excluding spontaneous abortions (n=238), terminated gestations (n=15), ectopic 
pregnancies (n=2), and stillbirths (n=17) to give all participants the same temporal window for 
potential exposure to allow for more comparable periods for exposure. Finally, multiple births 
(n=275), pregnancies lost to follow up/withdrew consent (n=241), and pregnancies that had not 
yet completed gestation at the time of analysis (n=360; categories not mutually exclusive) were 
removed, resulting in 3,291 women. Several of the MotherToBaby Pregnancy Studies were 
focused on women with particular conditions such an autoimmune disease or asthma.47 To more 
accurately reflect the female population in the United States and Canada, prevalence of 
participants with an autoimmune disease and with asthma were randomly down sampled to 
reported population prevalence of 3% and 10% of the sample48,49 respectively, bringing the 
sample total to 1,035 women.  
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3.4 Statistical Analysis 
Maternal characteristics were stratified by opioid use status to examine the differences 
among those who did and did not use opioids during pregnancy. Counts and percentages were 
used for categorical variables and means and standard deviations were used for continuous 
variables. Proportions were given for indications for use and separated by indication category, as 
well as for type of opioid used separated by indication categories and overall number of reports. 
Counts of opioid use per U.S. state grouped into regions were examined for geographic variation.  
Prevalence of opioid use was assessed by stage of pregnancy (before LMP, Trimester 1, 
Trimester 2, and Trimester 3) and by number of trimesters used (one, two, or all three 
trimesters). The variable “before LMP” was limited to 1 week before the participant’s estimated 
first week of pregnancy. Trimester 1 included exposure from weeks 1-12, Trimester 2 included 
exposure from weeks 13-26, and Trimester 3 included exposure from weeks 27-42 of the 
pregnancy or delivery, whichever occurred first. Proportions were out of total number of 
participants who used opioids. To evaluate frequency of opioid use within each trimester, 
interquartile ranges and mean number of weeks used were reported. All data were analyzed using 
JMP® 14.1.0 software.50  
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CHAPTER 4: RESULTS 
The demographic characteristics of the study population are presented in Table 1. Of the 
1,035 women in this study, 67 (6.5%) reported any opioid use during pregnancy. The mean ages 
for women who had taken opioids and those who had not were approximately 33 years and 32.5 
years, respectively. Both groups—those who used opioids and those who did not—were largely 
White (88% and 87%, respectively) and Non-Hispanic/Latina (88% and 87%, respectively). 
However, the proportion of women who had low SES and the proportion of women who were 
overweight or obese were each higher among those who had taken opioids than among those 
who did not (16% vs. 9% and 46% vs. 32%, respectively). On average, women who took opioids 
also had less education, with 16.5% having only a high school diploma or less, while only 8% of 
women who had not taken opioids completed only high school or less. The proportion of women 
who had earned a graduate-level degree was greater among women who had not taken opioids 
than among those that had (37.7% vs. 22.4%). Among opioid users, the proportions of reported 
comorbid conditions—autoimmune disease(s), asthma, depression, anxiety disorder, and other 
mental health disorders—were all about 1.5-1.6 times higher than the proportions in the non-user 
group. The proportion of any tobacco use was three times higher for women that used prescribed 
opioids than for those who did not, with 12% and 4% using tobacco, respectively.  
In terms of pregnancy-related characteristics, women who used prescription opioids also 
more frequently reported having a history of one or more terminated pregnancies than women 
who did not use opioids during pregnancy (18% and 9.5%, respectively). The proportion of 
women whose pregnancy was unplanned and the proportion of women who had one or more 
changes in paternity between children were each 1.6 times larger for opioid-using women than 
the proportion for non-users. 
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Data on the timing and duration of opioid use are presented in Table 2. Percentages of 
women who took opioids during each stage of pregnancy were relatively similar. The number of 
trimesters used was far less similar with just 6.3% of opioid-using participants using an opioid 
during all three trimesters of pregnancy. Three quarters of opioid-using participants used during 
one of the three trimesters.  
In Table 3, the number of weeks of opioid use was reported by pregnancy stage as well as 
by total duration of the pregnancy. Number of weeks women used opioids were relatively similar 
per trimester, ranging from no use in the 25% quartile to about 2 weeks used for each trimester in 
the 75% quartile.  
Of the 67 participants who reported opioid use (see Table 4), there were 92 specific 
indications reported (29 chronic and 63 acute). The most frequently reported indication overall 
was acute illness or injury, which included musculoskeletal injuries, infections, kidney stones, 
acute abdominal pain, and dental-related pain. Slightly over half of the chronic indications were 
for migraine.  
The types of opioids prescribed differed depending on whether they were prescribed for 
chronic or acute indications (see Table 5). For chronic indications, the most commonly 
prescribed opioid was hydrocodone (37%) followed by oxycodone and codeine (both 18.5%). 
The opioids for acute indications were more evenly distributed. Overall, hydrocodone (29%) and 
codeine (27%) were the most prescribed opioids. The least prescribed opioids were Fentanyl 
(2%) and propoxyphene (1%).  
Table 6 displays the distribution of opioid use by geographic region. The vast majority of 
the 1,035 participants were United States residents. The region with both the fewest total 
participants and lowest percentage of opioid users was Canada, with only 4% of the 67 total 
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participants reporting opioid use. In the United States, the prevalence of opioid use by region 
ranged from 4.3% of Midwestern participants to 8.9% of the participants in the Pacific region. 
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CHAPTER 5: DISCUSSION 
5.1. Summary of Findings 
Because of the large number of opioids currently being prescribed in the United States 
and the potential for adverse birth outcomes associated with prenatal opioid use,1,2 this study 
aimed to describe prescription opioid use among a prospective cohort of pregnant women. 
Specifically, this study analyzed prevalence of prescription opioid use, characteristics of mothers 
with prescription opioids during gestation, as well as timing, duration, and indication of use. 
Overall, in the sample of 1,035 pregnant women residing in the U.S. or Canada, approximately 
6.5% reported any opioid use—as prescribed by their healthcare provider—during their 
pregnancy.  
Women who used prescription opioids during pregnancy on average had less education, 
lower SES, were more likely to be overweight/obese, and more likely to be diagnosed with a 
comorbid condition (including autoimmune disease(s), asthma, depression, anxiety, and other 
mental health disorder(s)) than women who did not use opioids. They also had lower proportions 
of planned pregnancy and higher proportions of tobacco use during pregnancy, paternity 
change(s), prior spontaneous abortion(s), prior terminated abortion(s), and births via Cesarean 
delivery, compared to their counterparts.  
 
5.2. Comparison to the Literature 
To our knowledge, this is the first prospective cohort study to describe both prescription 
opioid use among a national sample of pregnant women in the U.S. and Canada as well as the 
maternal characteristics of those who used prescription opioids. However, there have been a few 
previous studies that have investigated similar trends among cohorts in different populations. 
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5.2.1. Prevalence of Prescription Opioid Use 
Over the study period (2004-2018), 6.5% of women in our sample used prescription 
opioids at some point during their pregnancies. The prevalence of prescribed opioid use among 
pregnant women has varied considerably among different cohorts. For example, in a prospective 
cohort study that followed 1.1 million pregnant women enrolled in Medicaid in the U.S. between 
2000-2007, 21.6% of participants “filled a prescription opioid during pregnancy.”37 Another 
Medicaid-enrolled cohort of 277,555 pregnant women in Tennessee found that between 1995-
2009, 29% of the participants filled a prescription for an opioid.38 In a study by Bateman et al., 
which followed 534,500 pregnant commercial insurance beneficiaries in the U.S. from 2005-
2011, 14.4% of participants filled a prescription for opioids.51  
A possible explanation for the difference in the percent of women prescribed opioids 
between the MotherToBaby cohort and these other cohorts could be because the data from these 
cohorts were based solely on information from insurance records, so it is unclear if this number 
accurately reflects the number of women who actually used the prescribed opioids after they 
were filled. The data from the MotherToBaby cohort consists of self-reported dates of use and 
reasons for use, decreasing the potential for exposure misclassification from reliance on claims 
data. Another reason opioid prescription was more common among these cohorts may have been 
because the dates of the study periods exactly coincided with the years when opioid prescription 
rates began increasing drastically in the general U.S. population, whereas our study period 
included years after there was an overall decrease in prescriptions in the wake of the opioid 
epidemic.1,2,11,13 Finally, there is likely a selection bias in our study due to the types of women 
who have the time and resources to volunteer for a study relatively early in gestation and 
continue participation through gestation. 
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Similar studies have been conducted in Canada,52 Sweden,53 and Norway25,54,55 and have 
reported proportions of perinatal opioid use far lower than the 6.5% found among our sample of 
women. The Canadian cohort study, which just included fee-for-service medical claims data 
from pregnant women residing in Manitoba, found that among the 175,174 pregnant women 
between 2001-2013, approximately 3-4% had used a prescription opioid per trimester.52 In the 
Scandinavian studies, which utilized some of the largest national pregnancy and birth cohorts in 
the world, prevalence was even smaller. For example, of 102,995 women who gave birth in 
Sweden in 2007, just 1.4-1.8% per trimester had reported prescription opioid use.53 A cohort 
study by Handal et al. used data from the Medical Birth Registry of Norway and the Norwegian 
Prescription Database between 2004-2008 and found that 3% of women were prescribed opioids 
at some point during pregnancy.54 Data from the 51,679 pregnancies in the Norwegian Mother 
and Child Cohort Study (MoBa) found that prescription opioid use occurred in only 1.7% of 
pregnancies.55 An earlier study using the MoBa data found that among 67,982 women between 
1999-2006, 3.9% had used codeine specifically during pregnancy.25 While these cohorts all 
reflect our sample more closely in terms of race, ethnicity, SES, and educational attainment, the 
large difference in prescription opioid rates for pregnant women is likely due to there being a 
much lower prevalence of prescription opioids in general in these countries compared to the 
United States.56,57 This is especially true during the mid-2000’s when most of these cohorts were 
examined. 56,57   
Not surprisingly, studies that more closely mirrored our sample demographics also 
yielded similar results for prevalence of prenatal opioid use. For example, in a cohort of 2,748 
pregnant women from Massachusetts and Connecticut, 6% reported using opioids that were 
prescribed to them at some point during their pregnancy.58 This cohort was the most similar to 
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ours in terms of race, ethnicity, and educational attainment compared to any of the other cohorts. 
This pattern suggests that our sample is likely an accurate estimation for only a subset of 
American and Canadian pregnant women. 
5.2.2. Timing and Duration of Opioid Use 
Regardless of the overall prevalence of prescription opioid use during pregnancy, nearly 
each of these studies reported similar trends of short-term use across each trimester. This was 
also true for the U.S. insurance-based cohorts37,38,51 as well as the Scandinavian cohorts.53-55 We 
also found that most participants had only taken opioids in one of the three trimesters. This too 
was consistent with the studies in Norway25,54,55 and in the United States.37,51  
5.2.3. Indications for Opioid Prescription 
In this sample, opioids were most often prescribed for acute illnesses and injuries, 
followed by chronic migraines. Taken together, surgeries and procedures, cold and flu, and 
chronic pain constituted roughly a third of all reasons for prescription. Based on these findings, it 
is not surprising that the average number of weeks of opioid use was just one or two weeks per 
trimester and that the majority of women took opioids during only one of the three stages of 
pregnancy. This pattern of use in pregnant women differs from those found in the general 
population. For example, a 2018 retrospective cohort study of 1.3 million Americans over 14 
years of age found that chronic pain conditions were the most common indication for people 
without a history of cancer diagnosis to receive opioid prescriptions.59 A population-based cohort 
study conducted in Canada also published different findings in 2018.60 The results of this study 
were that dental procedures, followed by postsurgical pain, were the two most frequently 
reported indications for first-time opioid prescriptions.60 It is likely that because there is more 
hesitancy, both by providers and women, for using medications during pregnancy, the types of 
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reasons for opioid prescription differ in this population. Pregnant women may also be less likely 
to schedule surgeries or dental procedures during the course of their pregnancy (other than in the 
case of time-sensitive emergencies), which could account for the differences in indications 
between pregnant women and the general adult population.  
The national cohort of Medicaid-enrolled pregnant women in the U.S. was the only study 
among these to also examine specific indications for use.37 Their results showed that the most 
commonly reported indications for opioid prescriptions were abdominal pain (48.4%), low back 
pain (33%), headache syndromes (not including migraine) (13.3%), joint pain (11.2%), and 
migraines (7.9%).37 The discrepancy in indications reported may have been due to the way that 
indications were grouped in our study. For example, in the MotherToBaby cohort, indications 
such as abdominal pain and back pain were common but were grouped into either “acute illness 
or injury” or “chronic pain” depending on the description of the indication and duration of the 
prescription. Among women in our cohort, migraines were also a far more common reason for 
opioid prescription than in the Medicaid-enrolled cohort.  
5.2.4. Types of Opioids Prescribed 
Of the 94 unique prescriptions reported in our sample, nearly three quarters were for 
hydrocodone (28.7%), codeine (26.6%), and oxycodone (18.1%). These three opioids were 
frequently reported as the most commonly prescribed to pregnant women in U.S. studies.38,51,58 
However, among Medicaid-enrolled pregnant women, both codeine and hydrocodone were 
reported as most prescribed, but oxycodone was not.37 In the Norwegian cohort studies by 
Handal et al. and by Skovlund et al., codeine represented the overwhelming majority—94.5%54 
and 89.6%,55 respectively—of opioids prescribed to pregnant women.  
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A minor difference between our results and others is that morphine and hydromorphone 
were used semi-frequently relative to the most (oxycodone, hydrocodone, and codeine) and least 
used opioids (fentanyl, tramadol, propoxyphene). The study by Bateman et al. showed morphine 
to be one of the least used opioids and did not have any reports of hydromorphone being 
prescribed.51 However, our findings were similar to those of the study conducted among 
Massachusetts and Connecticut residents.58 Smith et al. reported morphine and hydromorphone 
as the middle-used opioids, followed first by tramadol and then fentanyl.58 Again, this similarity 
could be due to the fact our cohorts are the most demographically similar of those previously 
described.  
Of note, tramadol is not technically an opioid by definition because it is not derived from 
opium61 and thus may not have been measured in each of these studies. However, tramadol was 
included in our analysis because the drug acts like an opioid by targeting the same pain receptors 
as traditional opioids.61 With that said, as of 2017 the U.S. Food and Drug Administration (FDA) 
officially has considered it a narcotic, specifically referring to it as an opioid.62  
It is also worth noting that several of the opioids prescribed to participants in this study 
were in the form of combination medications that contain acetaminophen (such as Tylenol® 
products containing codeine) or another non-narcotic pain reliever, as is frequently done in the 
general population. These specific combinations have not been included in the analysis but rather 
were coded into the corresponding opioid category (i.e. which opioid ingredient was used). 
Including a wider definition of opioids may have contributed to a more heterogeneous report of 
opioid type. Also, there was a very low number of prescriptions for propoxyphene, which could 
have been due to the FDA’s investigation of harms associated with the drug in the late 2000’s 
and its ultimate removal from the U.S. market in 2010.63  
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Data on doses per opioid prescribed were not included in our analysis due to the lack of 
dose standardization across the many types of opioids. Morphine-milligram equivalent (MME) 
scores are the most used method for standardizing doses across the different types of opioids.64,65 
However, there is mixed evidence about whether these instruments are valid. Due to evidence 
showing unreliability and inconsistency with the MME conversion method, 64,65 dose was not 
included at this time. Dose was frequently excluded from the existing cohort studies as well.  
5.2.5. Maternal Characteristics 
While overall prevalence of prescription opioid use generally differed among cohorts, our 
descriptions of maternal characteristics more common in those who were prescribed opioids is 
largely consistent with the existing literature. For example, we found that almost half of women 
prescribed opioids had pre-pregnancy BMIs considered overweight or obese, whereas less than a 
third of non-users were overweight or obese. In the study by Skovlund et al., the proportion of 
Norwegian women who used opioids increased as BMI increased.55 Similarly, Henriksen et al. 
also reported that codeine use during pregnancy was more common in people with an 
overweight/obese BMI.25  
Another common finding was that educational attainment was frequently reported in 
relation to opioid use. We found that the group who were prescribed opioids had double the 
proportion of women with less than a high school degree than the group of participants that did 
not take opioids. Other studies reported that opioid use was less common with more 
education25,55 and more common among those with less than a high school education.50 
Participants who had prior disabilities or medical conditions38,55,58 (such as autoimmune 
diseases,25 asthma,25 and mental health disorders,25,58 had reported consumption of tobacco 
(including smoking cigarettes)25,55,58 or alcohol25 during pregnancy, or had taken antidepressant 
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medication during pregnancy,55,58 were also more likely to have received an opioid prescription 
during pregnancy. Other than alcohol use during pregnancy, each of these maternal factors were 
also more common among those who were prescribed opioids in our sample.  
5.2.6 Geographic Distribution 
Findings from this study show a relatively small geographical difference in the 
prevalence of prenatal opioid use proportions compared to the cohort of Medicaid-enrolled 
pregnant women that had “substantial regional variation” for the proportion of women who fill 
an opioid prescription depending on their home state.37 The prevalence ranged from 9.5% to 
41.6% with the highest proportions in Utah, Idaho, New Hampshire, Wyoming, and Tennessee. 
However, this study population only included women on Medicaid and used data collected 
between 2000 and 2007, which was before local, state, and national policies were implemented 
to reduce the overall prescription of opioids.  
A 2017 NIH report showed that opioid overdose death rates in the U.S. varied greatly 
across states.13 The highest rates of opioid overdose deaths occurred in Maine, New Hampshire, 
Massachusetts, Maryland, District of Columbia, West Virginia, Ohio, and Kentucky, and the 
very lowest rates were in California, Texas, and Hawaii.13 These rates do not correspond with the 
proportions of maternal opioid use from the present study, which found higher rates to be in 
“Pacific” states (including California and Hawaii) and lower rates in the “Midwest” states 
(including Ohio) and “South” states (including Maryland, District of Columbia, West Virginia, 
and Kentucky). However, there was also a large number of states for which there was no 
enrollment, so the distribution may look different in reality. Opioid-related overdose deaths are 
also not an ideal comparison with prescription opioid use among pregnant women. However, 
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most of the existing cohort studies in the U.S. and Canada38,51,52,58 either could not or did not 
measure national geographic distribution of perinatal prescription opioid use.  
 
5.3 Strengths 
One strength of this study is the large, prospectively collected sample of over 1,000 
women. This is especially important when looking at opioid use, which typically encompasses 
such a small portion of the population. Additionally, the original group of eligible participants 
was down-sampled to better reflect the distribution of autoimmune disease of the U.S. and 
Canadian populations. Due to the nature of telephone-based interviews, the participants may 
have been more comfortable providing honest and detailed responses. Further, this analysis 
captures opioids as taken, as opposed to opioids as prescribed, which can be significantly 
different, and limits inference possible from large administrative claims database studies such as 
Medicaid. 
 
5.4 Limitations 
Several limitations must be considered when interpreting these findings. First, the 
recruitment methods lend themselves to introducing two types of selection bias. For example, 
because some women were recruited online and/or through advertisements, volunteer bias may 
skew the sample away from the general population that was aimed for. Women with more free 
time, who may be more trusting of medical advice, or who do not feel they need to hide socially 
undesirable behaviors may be more willing to volunteer. Second, the majority of women enrolled 
were made aware of the studies after calling experts to obtain information during pregnancy. 
These women are actively seeking health information and may be healthier than the general 
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population. Also, the sample differed from the general population of pregnant women in North 
America by race, ethnicity, geography, socioeconomic status, and education. Therefore, these 
results may not be generalizable to all pregnant women. There is also some risk for recall bias 
due to the self-report data collection methods. The data from the present study did not include 
participant zip code, so participants were unable to be coded as residents of either rural or urban 
areas. This could be an important addition to future studies because early evidence has found that 
between 2004-2013 in the U.S., maternal opioid use “increased disproportionately in rural 
counties…relative to urban counties.”66  
 
5.5 Conclusions  
Among the women in the MotherToBaby cohort, those who use opioids during 
pregnancy differed from those who did not use opioids on the basis of SES, educational 
attainment, BMI, comorbid health conditions, and several different pregnancy characteristics and 
outcomes. Reassuringly, most women used an opioid during one or two different weeks of the 
pregnancy during just one trimester of the pregnancy. The most common reason for opioid use 
included acute illnesses and injuries.  
The next step in our research will be to examine the actual birth outcomes for women in 
this sample. Recent changes in opioid prescribing behavior among health care providers warrant 
continued study of prevalence among pregnant women over the next decade. Given that this 
study population was down-sampled to accommodate for the oversampling of women with 
autoimmune diseases and asthma that were in the original dataset and that women with these 
conditions may be more likely to use opioids than the general population, another analysis could 
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examine if they are also more likely to be prescribed opioids during pregnancy as well as 
corresponding birth outcomes.  
Additional studies with a more generalizable sample could greatly contribute to the 
existing literature on this topic. For example, because perinatal opioid use may impact whether a 
woman has a live birth,8,23,24,27-29 similar analyses could be performed to include both successful 
and unsuccessful pregnancies. It is clear from the literature that researchers have only begun to 
explore the risks of negative outcomes for mothers and children exposed to opioids during 
pregnancy. While only 6.5% took opioids during pregnancy, when applying that proportion to 
the number of pregnancies in the U.S. and Canada per year (approximately 6.3 million67 and over 
380,00068) hundreds of thousands of pregnant women (and their children) will be exposed to 
opioids during pregnancy. Therefore, it is undoubtedly important to determine the safety of 
opioid use during pregnancy and the risks of pregnancy complications, adverse birth outcomes, 
and long-term consequences for mother and child. 
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APPENDIX 
 
Table 1: Maternal characteristics by prescription opioid use exposure category (N=1,035) from 
women enrolled in MotherToBaby pregnancy study between 2004-2018 
 
Characteristics No Opioid Use  N= 968 (93.5) 
Any Opioid Use 
N=67 (6.5) 
Age (years), mean (±SD) 32.51 (±5.03) 33.25 (±4.54) 
     
Race, N (%)     
White 843 (87.1) 59 (88.1) 
Black  45 (4.7) 3 (4.5) 
Asian 50 (5.2) 3 (4.5) 
Pacific Islander 1 (0.1) − − 
Indian/Native American 10 (1.0) 1 (1.5) 
Other  17 (1.8) 1 (1.5) 
NAa 2 (0.2) − − 
     
Ethnicity, N (%)     
Hispanic/Latina 121 (12.5) 8 (11.9) 
Non-Hispanic/Latina 845 (87.3) 59 (88.1) 
NA 2 (0.2) − − 
     
Highest education level, N (%)     
Less than 9th grade 3 (0.3) − − 
Junior high school (9th) 8 (0.8) 3 (4.5) 
Some high school (10th or 11th) 10 (1.0) 2 (3.0) 
High school graduate 57 (5.9) 6 (9.0) 
Some college 159 (16.4) 18 (26.9) 
College or university graduate 366 (37.8) 23 (34.3) 
Post-college graduate 365 (37.7) 15 (22.4) 
     
SESb, N (%)     
Low SES 88 (9.1) 11 (16.4) 
High SES 859 (88.7) 56 (83.6) 
NA 21 (2.2) − − 
     
Pre-pregnancy BMIc, N (%)     
Underweight (<18.5) 40 (4.1) 2 (3.0) 
Normal (18.5 – 24.9) 613 (63.3) 33 (49.3) 
Overweight/Obese (≥25) 308 (31.8) 31 (46.3) 
NA 7 (0.7) 1 (1.5) 
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Table 2: Maternal characteristics by prescription opioid use exposure category (N=1,035) from 
women enrolled in MotherToBaby pregnancy study between 2004-2018 
 
   
Characteristics No Opioid Use  N= 968 (93.5) 
Any Opioid Use 
N=67 (6.5) 
     
Autoimmune disease(s) 28 (2.9) 3 (4.5) 
Asthma 94 (9.7) 10 (14.9) 
Depression 180 (18.6) 15 (22.4) 
Anxiety disorder(s) 98 (10.1) 11 (16.4) 
Other mental health disorder(s) 53 (5.5) 6 (9.0) 
Antidepressant medication use 69 (7.1) 7 (10.4) 
Any tobacco use  37 (3.8) 8 (11.9) 
Prenatal vitamin use 940 (97.1) 66 (98.5) 
1st week prenatal vitamin use 
(gestational week), (mean±SD) -7.30 (±43.24) -5.32 (±34.28) 
     
Last week used alcohol, N (%)     
Never used 477 (49.3) 35 (52.2) 
LMP – week 4 320 (33.0) 22 (32.8) 
Week 5 – week 34 92 (9.5) 8 (11.9) 
Week 35-40 79 (8.2) 2 (3.0) 
     
SABd History, N (%)     
None 717 (74.1) 44 (65.3) 
1 or more SABs 251 (25.9) 23 (34.3) 
     
TABe History, N (%)     
None 876 (90.5) 55 (82.1) 
1 or more TABs 92 (9.5) 12 (17.9) 
     
Planned Pregnancy, N (%)     
Planned 753 (77.8) 44 (65.7) 
Unplanned 214 (22.1) 23 (34.3) 
NA 1 (0.1) − − 
     
Paternity change, N (%)     
None 766 (79.1) 53 (79.1) 
1 or more changes 114 (11.8) 13 (19.4) 
NA 88 (9.1) 1 (1.5) 
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Table 3: Maternal characteristics by prescription opioid use exposure category (N=1,035) from 
women enrolled in MotherToBaby pregnancy study between 2004-2018 
 
     
Characteristics No Opioid Use  N= 968 (93.5) 
Any Opioid Use 
N=67 (6.5) 
     
Delivery method, N (%)     
Vaginal delivery 699 (72.2) 45 (68.2) 
Cesarean delivery  266 (27.5) 21 (31.8) 
NA 3 (0.3) 1 (1.5) 
     
Gest. age delivery (wks)f, mean (±SD) 39.20 (±1.76) 38.63 (±3.27) 
Parity, mean (±SD) 0.75 (±0.98) 1.16 (±1.18) 
 
a NA, no answer 
b SES, socioeconomic status (High is Hollingshead categories of 1-3, low is categories 4 or 5) 
c BMI, body mass index (weight divided by height2) 
d SAB, spontaneous abortion 
e TAB, terminated abortion 
f Participants missing from no-opioid use category (n=4) and opioid use category (n=1)  
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Table 4: Prevalence of prescription opioid use by trimester (2004-2018) and by cumulative 
trimesters 
 
 
Used 
Prescription 
Opioids (Y/N) 
 
% of Total 
Opioid Users 
(N = 64a) 
Pregnancy Stageb   
Before LMP 9 (14.1) 
Trimester 1 26 (40.6) 
Trimester 2 29 (45.3) 
Trimester 3 29 (45.3) 
   
Number of Trimesters Used   
1 trimester 48 (75.0) 
2 trimesters  12 (18.8) 
3 trimesters (all) 4 (6.3) 
a 3 participants did not report dates of opioid use  
b LMP, last menstrual period; Trimester 1, gestational weeks 1-12; Trimester 2, gestational weeks 
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Table 5: Number of weeks used a prescribed opioid at least once by trimester and by cumulative 
pregnancy duration (average and interquartile range) 
 
 Mean (SD) Median Q1 Q3 
Total Duration 5.75 (±8.44) 2.0 1.0 6.0 
      
Trimesters      
Trimester 1 1.56 (±3.10) 0.0 0.0 1.75 
Trimester 2 2.23 (±4.00) 0.0 0.0 2.0 
Trimester 3 1.81 (±3.08) 0.0 0.0 2.0 
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Table 6: Indications for opioid prescription use by chronic and acute indication 
 
 
Indications 
Reported 
N = 92ab 
Indications by 
Use Category 
(%) 
Indications by 
Total Reports 
(%)  
    
Chronic Indications  29 (100.0) (31.5) 
Chronic Pain 9 (31.0) (9.8) 
Chronic Migraines 15 (51.7) (16.3) 
Autoimmune Disease 5 (17.2) (5.4) 
 
    
Acute Indications 63 (100.0) (68.5) 
Acute Illness/Injury 41 (65.1) (44.6) 
Surgery/Procedure 10 (15.9) (10.9) 
Cold/Flu 10 (15.9) (10.9) 
ER Visit (Reason unknown)  2 (3.2) (2.2) 
a 2 prescriptions did not have a corresponding indication reported 
b Of the 67 participants who used opioids, there were 94 separate prescriptions reported 
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Table 7: Prevalence of different types of prescribed opioids by indication category (acute or 
chronic indications) and by total prescriptions 
 
 
Total 
Prescriptions 
N= 94 (100.0) 
Prescriptions 
per Acute 
Indication 
N= 65c (100.0) 
Prescriptions per 
Chronic 
Indication 
N= 27c (100.0) 
Opioid Classification       
Morphinea 11 (11.7) 8 (12.3) 2 (7.4) 
Hydromorphone 8 (8.5) 7 (10.8) 1 (3.7) 
Hydrocodone 27 (28.7) 17 (26.2) 10 (37.0) 
Oxycodone 17 (18.1) 12 (18.5) 5 (18.5) 
Codeineb 25 (26.6) 19 (29.2) 5 (18.5) 
Tramadol 3 (3.2) − − 3 (11.1) 
Fentanyl 2 (2.1) 2 (3.1) − − 
Propoxyphene 1 (1.1) − − 1 (3.7) 
a 1 prescription for morphine had no indication reported 
b 1 prescription for codeine had no indication reported 
c 2 prescriptions did not report an indication, (n=92) 
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Table 8: Prevalence of prescription opioid use by geographic region in U.S. and Canada 
 
 Region Total 
N= 1035 
Any Opioid 
Use 
N= 67 
% of Region 
Total 
    
Canadaa 76 3 (4.0) 
    
United States 863 59 (6.8) 
Pacific 247 22 (8.9) 
Mountain 180 15 (8.3) 
Midwest 116 5 (4.3) 
South 200 9 (4.5) 
Northeast 120 8 (6.7) 
NA 96 5 (5.2) 
a Data from participants in Northwestern Territories (a federal territory of Canada, not a province) were included  
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